

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/E2A804A427A7EN.html>

Date: February 2020

Pages: 68

Price: US\$ 3,500.00 (Single User License)

ID: E2A804A427A7EN

Abstracts

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Review, H1 2020'; Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 18 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene. It stimulates migration of melanoma cells. It has a role in induction of parturition. It is involved in cell proliferation and adipose tissue development.

The report 'Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Review, H1 2020' outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System, Cardiovascular, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Systemic Sclerosis (Scleroderma), Breast Cancer, Inflammation, Inflammatory Bowel Disease, Lung Cancer, Multiple Sclerosis, Atherosclerosis, Chronic Obstructive Pulmonary Disease (COPD), Fibrosis, Ischemic Stroke, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Lung Cancer, Musculoskeletal Pain, Osteoarthritis Pain, Ovarian Cancer, Pain, Solid Tumor, Thyroid Cancer and Visceral Pain.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)

The report reviews Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics and enlists all their major and minor projects

The report assesses Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Overview

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Companies Involved in Therapeutics Development

Blade Therapeutics Inc

Boehringer Ingelheim International GmbH

Eli Lilly and Co

Fidelta Ltd

Galapagos NV

Galecto Biotech AB

iOnctura SA

LegoChem Biosciences Inc

Ono Pharmaceutical Co Ltd

Ribomic Inc

Sansho Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

X-Rx Inc

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Drug Profiles

2-CCPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBT-877 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLD-0409 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IOA-289 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-8430506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAT-048 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ATX and EGFR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Autotaxin for Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Autotaxin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TJC-0265 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TJC-0316 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziritaxestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Dormant Products

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Product Development

Milestones

Featured News & Press Releases

- Jan 29, 2020: Orphan Drug Designation for GLPG1690 in systemic sclerosis
- Dec 05, 2019: Galapagos completes recruitment of NOVESA trial in systemic sclerosis
- Sep 29, 2019: Bridge Biotherapeutics presents positive results from phase 1 clinical study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) treatments at the ERS International Congress 2019
- May 20, 2019: Bridge Biotherapeutics announces data presentation from first-in-human study of BBT-877 for idiopathic pulmonary fibrosis
- Jan 24, 2019: X-Rx announces FDA acceptance of IND application for X-165
- Jan 16, 2019: Bridge Biotherapeutics announces FDA Orphan Drug Designation for BBT-877 in idiopathic pulmonary fibrosis (IPF)
- Jan 07, 2019: Galapagos starts Phase IIa trial of GLPG1690 for systemic sclerosis
- Dec 17, 2018: Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
- Dec 17, 2018: Bridge Biotherapeutics announces FDA clearance of IND for its BBT-877, an autotaxin inhibitor for IPF
- Nov 18, 2018: Bridge Biotherapeutics files investigational new drug application for BBT-877, an autotaxin inhibitor for idiopathic pulmonary fibrosis
- Aug 22, 2018: Bridge Biotherapeutics presented preclinical study results on BBT-877, an autotaxin inhibitor at the IPF Summit 2018
- May 20, 2018: GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
- Apr 12, 2018: Galapagos announces ISABELA Phase 3 program in IPF
- Aug 09, 2017: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
- Sep 06, 2016: Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Blade Therapeutics Inc, H1 2020
Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Fidelta Ltd, H1 2020
Pipeline by Galapagos NV, H1 2020
Pipeline by Galecto Biotech AB, H1 2020
Pipeline by iOnctura SA, H1 2020
Pipeline by LegoChem Biosciences Inc, H1 2020
Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Pipeline by Ribomic Inc, H1 2020
Pipeline by Sansho Co Ltd, H1 2020
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2020
Pipeline by X-Rx Inc, H1 2020
Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Blade Therapeutics Inc

Boehringer Ingelheim International GmbH

Eli Lilly and Co

Fidelta Ltd

Galapagos NV

Galecto Biotech AB

iOnctura SA

LegoChem Biosciences Inc

Ono Pharmaceutical Co Ltd

Ribomic Inc

Sansho Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

X-Rx Inc

I would like to order

Product name: Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/E2A804A427A7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E2A804A427A7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

